Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon

doi:10.3748/wjg.v22.i4.1650

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10810)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

850

WORD

353

HTML

6455

Figures (1-2)

260

Tables (1-4)

240

Sum=8158

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1155

Download

1497

Sum=2652

Jan 28, 2016 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 28, 2016; 22(4): 1650-1663
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1650

Table 4 Considerations with direct acting antivirals in renal dysfunction

DAA agent or combination	Issues in renal dysfunction
Sofosbuvir	Contraindication in GFR < 30 mL/min due to insufficient safety data[127]
Simeprevir	No dose adjustment[75]
Ledipasvir	Limited data; no theoretical concerns[127]
PTV/r + OMB + DSV	Safe and effective and no dose adjustment in ESRD[100]
Daclatasvir	No dose adjustment[78]
Elbasvir/Grazoprevir	Safe and effective and no dose adjustment in ESRD[101]

DAA: Direct acting antiviral; ESRD: End stage renal disease; GFR: Glomerular filtration rate; PTV: Paritaprevir; r: Ritonavir; OMB: Ombitasvir; DSV: Dasabuvir.

Citation: Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol 2016; 22(4): 1650-1663
URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1650.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1650